Brokerages expect aTyr Pharma, Inc. (NASDAQ:LIFE – Get Rating) to post ($0.44) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for aTyr Pharma’s earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.36). aTyr Pharma posted earnings per share of ($0.64) during the same quarter last year, which would suggest a positive year over year growth rate of 31.3%. The business is expected to announce its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that aTyr Pharma will report full-year earnings of ($1.78) per share for the current year, with EPS estimates ranging from ($1.93) to ($1.54). For the next year, analysts forecast that the business will post earnings of ($1.88) per share, with EPS estimates ranging from ($2.50) to ($1.15). Zacks’ earnings per share calculations are an average based on a survey of sell-side analysts that cover aTyr Pharma.
aTyr Pharma (NASDAQ:LIFE – Get Rating) last issued its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.10). During the same period last year, the business posted ($0.51) EPS.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP grew its stake in aTyr Pharma by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 226,712 shares of the biotechnology company’s stock valued at $1,694,000 after acquiring an additional 2,433 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of aTyr Pharma by 1.9% in the 3rd quarter. Renaissance Technologies LLC now owns 179,655 shares of the biotechnology company’s stock valued at $1,631,000 after buying an additional 3,400 shares during the period. Charles Schwab Investment Management Inc. purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at approximately $75,000. Qube Research & Technologies Ltd purchased a new stake in shares of aTyr Pharma in the 4th quarter valued at approximately $87,000. Finally, Virtu Financial LLC purchased a new stake in shares of aTyr Pharma in the 1st quarter valued at approximately $70,000. 77.96% of the stock is owned by institutional investors.
Shares of LIFE remained flat at $$3.00 during mid-day trading on Friday. 79,316 shares of the company traded hands, compared to its average volume of 90,696. aTyr Pharma has a 52-week low of $2.89 and a 52-week high of $13.10. The firm’s fifty day simple moving average is $4.56 and its 200 day simple moving average is $6.04. The stock has a market cap of $84.18 million, a PE ratio of -1.66 and a beta of 1.54.
aTyr Pharma Company Profile (Get Rating)
aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.
- Get a free copy of the StockNews.com research report on aTyr Pharma (LIFE)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.